• 3036 Citations
  • 28 h-Index
1990 …2020
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Mark Stein is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 17 Similar Profiles
Prostatic Neoplasms Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
docetaxel Medicine & Life Sciences
Castration Medicine & Life Sciences
Renal Cell Carcinoma Medicine & Life Sciences
gemcitabine Medicine & Life Sciences
Androgens Medicine & Life Sciences
Pharmacokinetics Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1990 2020

18F-Sodium fluoride PET/CT predicts overall survival in patients with advanced genitourinary malignancies treated with cabozantinib and nivolumab with or without ipilimumab

Lim, I., Lindenberg, M. L., Mena, E., Verdini, N., Shih, J. H., Mayfield, C., Thompson, R., Lin, J., Vega, A., Mallek, M., Cadena, J., Diaz, C., Mortazavi, A., Knopp, M., Wright, C., Stein, M., Pal, S., Choyke, P. L. & Apolo, A. B., Jan 1 2020, In : European Journal of Nuclear Medicine and Molecular Imaging. 47, 1, p. 178-184 7 p.

Research output: Contribution to journalArticle

Open Access

Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy

Hawley, J. E., Pan, S., Figg, W. D., Lopez-Bujanda, Z. A., Strope, J. D., Aggen, D. H., Dallos, M. C., Lim, E. A., Stein, M. N., Hu, J. & Drake, C. G., Mar 1 2020, In : Prostate. 80, 4, p. 336-344 9 p.

Research output: Contribution to journalArticle

Prostate-Specific Antigen
Immunosuppressive Agents
Prostatic Neoplasms
Cytokines
Androgens
18 Citations (Scopus)

A phase II trial of the aurora kinase a inhibitor alisertib for patients with castration-resistant and neuroendocrine prostate cancer: Efficacy and biomarkers

Beltran, H., Oromendia, C., Danila, D. C., Montgomery, B., Hoimes, C., Szmulewitz, R. Z., Vaishampayan, U., Armstrong, A. J., Stein, M., Pinski, J., Mosquera, J. M., Sailer, V., Bareja, R., Romanel, A., Gumpeni, N., Sboner, A., Dardenne, E., Puca, L., Prandi, D., Rubin, M. A. & 6 others, Scher, H. I., Rickman, D. S., Demichelis, F., Nanus, D. M., Ballman, K. V. & Tagawa, S. T., Jan 1 2019, In : Clinical Cancer Research. 25, 1, p. 43-51 9 p.

Research output: Contribution to journalArticle

Aurora Kinases
Castration
Tumor Biomarkers
Prostatic Neoplasms
Organoids
1 Citation (Scopus)

A phase I study of AT-101, a BH3 mimetic, in combination with paclitaxel and carboplatin in solid tumors

Stein, M. N., Goodin, S., Gounder, M., Gibbon, D., Moss, R., Portal, D., Lindquist, D., Zhao, Y., Takebe, N., Tan, A., Aisner, J., Lin, H., Ready, N. & Mehnert, J. M., Jan 1 2019, (Accepted/In press) In : Investigational New Drugs.

Research output: Contribution to journalArticle

Carboplatin
Paclitaxel
Neoplasms
Area Under Curve
Prostate

A phase I trial of MK-2206 and hydroxychloroquine in patients with advanced solid tumors

Mehnert, J. M., Kaveney, A. D., Malhotra, J., Spencer, K., Portal, D., Goodin, S., Tan, A. R., Aisner, J., Moss, R. A., Lin, H., Bertino, J. R., Gibbon, D., Doyle, L. A., White, E. P. & Stein, M. N., Oct 1 2019, In : Cancer chemotherapy and pharmacology. 84, 4, p. 899-907 9 p.

Research output: Contribution to journalArticle

Hydroxychloroquine
Tumors
Neoplasms
Exanthema
Fatigue